Corvus’ CPI-818 Shows Promising Early Results in T-cell Lymphomas, Data Finds
News
Twice-daily treatment with Corvus Pharmaceuticals‘ potential therapy for T-cell lymphomas, CPI-818, is showing promising safety and tolerability, and preliminary signs of efficacy, according to Phase 1/1b results. The early clinical ... Read more